Cancer Loyalty Card Study

Summary

Approximately 7,400 new cases of ovarian cancer are diagnosed each year in the United Kingdom (UK), and with over 4,000 women dying from the disease each year it is a particularly lethal form of cancer. The symptoms for ovarian cancer are not well known and vague, and most women are diagnosed at a late stage when the cancer has already spread around the abdominal cavity with poor prognosis. Novel methods are needed to improve earlier detection and thereby improve survival from this disease.

The Cancer Loyalty Card Study (CLOCS) proposes to use loyalty card data from two participating high street retailers to investigate purchase behaviour as an opportunity for cancer symptom surveillance. The investigators aim to conduct a case-control study of ovarian cancer patients matched with women without ovarian cancer and to explore public preferences for how to communicate potential outcomes of the commercial and health data linkages back to individuals.

Eligible participants will be women in the UK who own at least one loyalty card with the participating high street retailers. Of these women, those who have been diagnosed with ovarian cancer are eligible to participate in the study as cases, while women who have not been diagnosed with ovarian cancer are eligible to participate as controls.

Upon choosing to participate, all participants will be asked to complete a short questionnaire about well-established ovarian cancer risk factors and common symptoms either in the clinic (cases) or online/from a packet in the mail(controls). This information will be used in risk assessment for ovarian cancer of participants, which will be used at the analysis stage.

Conditions

• Ovarian Neoplasms

Interventions

OTHER

Risk Factor Questionnaire

For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.

OTHER

Clinical Questionnaire

For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.

Sponsors & Collaborators

• Cancer Research UK

  collaborator OTHER

• Imperial College Healthcare NHS Trust

  collaborator OTHER

• Sandwell & West Birmingham Hospitals NHS Trust

  collaborator OTHER

• University College London Hospitals

  collaborator OTHER

• County Durham and Darlington NHS Foundation Trust

  collaborator OTHER_GOV

• Walsall Healthcare NHS Trust

  collaborator OTHER

• Surrey and Sussex Healthcare NHS Trust

  collaborator OTHER

• Airedale NHS Foundation Trust

  collaborator OTHER

• Abertawe Bro Morgannwg University Health Board

  collaborator OTHER

• Gateshead Health NHS Foundation Trust

  collaborator OTHER

• Norfolk and Norwich University Hospitals NHS Foundation Trust

  collaborator OTHER

• The Leeds Teaching Hospitals NHS Trust

  collaborator OTHER

• NHS Lothian

  collaborator OTHER_GOV

• East Lancashire Hospitals NHS Trust

  collaborator OTHER

• University Hospitals Bristol and Weston NHS Foundation Trust

  collaborator OTHER

• Royal Surrey County Hospital NHS Foundation Trust

  collaborator OTHER

• Royal Marsden NHS Foundation Trust

  collaborator OTHER

• Velindre NHS Trust

  collaborator OTHER_GOV

• Cardiff and Vale University Health Board

  collaborator OTHER_GOV

• South Tees Hospitals NHS Foundation Trust

  collaborator OTHER

• West Hertfordshire Hospitals NHS Trust

  collaborator OTHER

• The Christie NHS Foundation Trust

  collaborator OTHER

• Manchester University NHS Foundation Trust

  collaborator OTHER_GOV

• NHS Greater Glasgow and Clyde

  collaborator OTHER

• Imperial College London

  lead OTHER

Principal Investigators

• James Flanagan, PhD · Imperial College London

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2019-11-04

Primary Completion

2022-01-31

Completion

2022-07-28

Countries

• United Kingdom

Study Locations